Tuesday, June 28, 2022 3:35:45 AM
EPI-7386 WAS SAFE AND WELL-TOLERATED AT ALL DOSE LEVELS
EPI-7386 SCHEDULES TESTED WITH PLASMA TARGET CONCENTRATIONS ACHIEVED AND CLINICALLY IMPORTANT EFFICACY SIGNALS
ESSA PHARMA INC - EXPECTS TO INITIATE PHASE 1B MONOTHERAPY EXPANSION STUDY IN Q3 2022
We are pleased with the progress in advancing our novel prostate cancer candidate EPI-7386 as a monotherapy in patients with advanced mCRPC.
We continue to be excited by our combination trials evaluating EPI-7386 with the four leading, commercially available antiandrogens in earlier line patient populations
I hope some huge portfolios get excited too...
Recent EPIX News
- ESSA Pharma to Present at the Jefferies Global Healthcare Conference • PR Newswire (Canada) • 05/30/2024 12:00:00 PM
- ESSA Pharma to Present at the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 11:01:47 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 11:00:36 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 • PR Newswire (Canada) • 05/14/2024 11:00:00 AM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024 • PR Newswire (US) • 05/14/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/06/2024 09:17:29 PM
- ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference • PR Newswire (US) • 04/09/2024 12:00:00 PM
- ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference • PR Newswire (Canada) • 04/09/2024 12:00:00 PM
- ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS • PR Newswire (US) • 03/08/2024 01:13:00 AM
- ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS • PR Newswire (Canada) • 03/08/2024 01:13:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 10:18:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:50:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 12:01:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 12:01:41 PM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 • PR Newswire (Canada) • 02/13/2024 12:00:00 PM
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023 • PR Newswire (US) • 02/13/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 04:29:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 01:27:19 PM
- ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (Canada) • 02/06/2024 01:00:00 PM
- ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/06/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 02:15:29 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2024 09:40:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2024 09:27:10 PM
- ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium • PR Newswire (Canada) • 01/25/2024 03:00:00 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM